Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taletrectinib vs Crizotinib in ROS1+ NSCLC (TRUST-III)
NCT06564324Phase 3Recruiting
- Sponsor
- Nuvation Bio
- Start
- Nov 2024
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of taletrectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nuvation Bio. Primary endpoint: Progression-Free Survival (Assessed by BIRC) at 49 months. Started Nov 2024; status: recruiting.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06564324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564324.